Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness in patients with psoriasis wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Iskandar, Ireny Y.K., Warren, Richard B., Lunt, Mark, Mason, Kayleigh J., Evans, Ian, McElhone, Kathleen, Smith, Catherine H., Reynolds, Nick J., Ashcroft, Darren M., Griffiths, Christopher E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869053/
https://www.ncbi.nlm.nih.gov/pubmed/29080680
http://dx.doi.org/10.1016/j.jid.2017.09.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869053/
https://www.ncbi.nlm.nih.gov/pubmed/29080680
http://dx.doi.org/10.1016/j.jid.2017.09.044

Ejemplares similares